

Correlative

UCI 14-25 Plasma Exosome Concentration in Cancer Patients Undergoing Treatment (Nelson)

UCI 16-01 (PAINT Cancer)-Pathway Analyses for Individualized Network Therapeutics for Cancer (Nelson)



Neo-Adjuvant - Squamous Cell Carcinoma

UCI 16-72 Randomized Double-Blind Phase 3 Study of Avelumab in Combination with Standard of Care Chemoradiotherapy (Cisplatin Plus Definitive Radiation Therapy) Versus Standard of Care Chemoradiotherapy in the Front-Line Treatment of Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Ejadi)

Metastatic

2nd Line

UCI 16-50 Phase 1b/2, Open-Label, Multicenter Study Assessing the Safety, Tolerability, Pharmacokinetics & Preliminary Anti-tumor Activity of MEDI4736 in Combination With AZD9150 or AZD5069 in Pts With Advanced Solid Malignancies & Subsequently Comparing AZD9150 & AZD5069 Both as Monotherapy & in Combination With MEDI4736 as Second Line Treatment in Pts With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (Nelson)

Neo-Adjuvant - Nasopharyngeal

NRG-HN001 Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA) (Ejadi)

Multiple Disease Sites

HEAD & NECK CANCER

UCI 16-96 A Phase I Study of the Highly-selective **RET Inhibitor**, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors **(Ou)**

UCI 18-78** A Phase I/II Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation **(Ou)**

UCI 18-101 ** A Phase I Dose Escalation Study Evaluating Safety, Tolerability and Pharmacokinetics of PF-06952229 in Adult Patients with Advanced Solid Tumors **(Uchio)**

UCI 18-103 ** Blood Sample Collection to Evaluate Biomarkers in Subjects with Untreated Solid Tumors **(Uchio)**

ECOG EAY131 Molecular Analysis for Therapy Choice (MATCH) (Larynx, Lip, Oral Cavity & Pharynx) **(Bota)**

SWOG S1609 DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors **(Bota)**

UCI 18-14 A Phase I, Open-Label, Multicenter Dose Escalation Study of RMC-4630 Monotherapy in Adult Patients with Relapsed/Refractory Solid Tumors **(Ou)**

UCI 18-19 An Open-Label, Phase Ib Multicenter Study of IBI308 in Subjects with Advanced/Metastatic Solid Malignancies **(Zhu)**

UCI 18-21 A Phase I/II Study of Oral LOXO-292 in Patients with Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors with RET Activation (LIBRETTO-001) **(Ou)**